Natural Product Research Division, Department of Biological and Biomedical Sciences, The Aga Khan University Medical College, Karachi-74800, Pakistan.
Lipids Health Dis. 2012 Jan 10;11:6. doi: 10.1186/1476-511X-11-6.
This study was undertaken to provide pharmacological basis for the medicinal use of Viola odorata Linn. in hypertension and dyslipidemia using the in vivo and in vitro assays.
Viola odorata leaves extract (Vo.Cr), which tested positive for alkaloids, saponins, tannins, phenolics, coumarins and flavonoids, caused a dose-dependent (0.1-1.0 mg/kg) decrease in mean arterial blood pressure in anaesthetized rats. In isolated guinea-pig atria, Vo.Cr equally inhibited force and rate of spontaneous atrial contractions. On the baseline of rat thoracic aortae (endothelium-intact and denuded), the plant extract caused phentolamine-sensitive vasoconstriction. When tested on phenylephrine (PE, 1 μM) and K(+) (80 mM)-induced vasoconstriction, Vo.Cr caused a concentration-dependent relaxation and also caused a rightward shift of Ca(++) concentration-response curves as well as suppression of PE (1 μM) control peaks in Ca(++)-free medium, similar to that caused by verapamil. In the presence of L-NAME, the relaxation curve of Vo.Cr was partially inhibited showing involvement of Nitric oxide (NO) mediated pathway. In Tyloxapol-induced dyslipidemia, Vo.Cr caused reduction in total cholesterol and triglyceride levels. In high-fat diet-induced dyslipidemia model, the plant extract caused a significant decrease in total cholesterol, LDL-C, atherogenic index and prevented the increase in average body weights, while it increased HDL-C.
These data indicate that the vasodilator effect of the plant extract is mediated through multiple pathways like inhibition of Ca(++) influx via membranous Ca(++) channels, its release from intracellular stores and NO-mediated pathways, which possibly explain the fall in BP. The plant also showed reduction in body weight and antidyslipidemic effect which may be due to the inhibition of synthesis and absorption of lipids and antioxidant activities. Thus, this study provides a pharmacologic rationale to the medicinal use of Viola odorata in hypertension and dyslipidemia.
本研究旨在通过体内和体外试验,为堇菜属植物在高血压和血脂异常中的药用提供药理学依据。
堇菜叶提取物(Vo.Cr)经检测含有生物碱、皂苷、单宁、酚类、香豆素和黄酮类化合物,可使麻醉大鼠的平均动脉血压呈剂量依赖性下降(0.1-1.0mg/kg)。在离体豚鼠心房中,Vo.Cr 同样抑制自发性心房收缩的力和速率。在大鼠胸主动脉(有内皮和无内皮)的基础上,植物提取物引起酚妥拉明敏感的血管收缩。在苯肾上腺素(PE,1μM)和 K(+)(80mM)诱导的血管收缩试验中,Vo.Cr 引起浓度依赖性的舒张,并使 Ca(++)浓度反应曲线向右移位,以及在无 Ca(++)介质中抑制 PE(1μM)对照峰,类似于维拉帕米引起的作用。在 L-NAME 存在下,Vo.Cr 的舒张曲线部分被抑制,表明涉及一氧化氮(NO)介导的途径。在 Tyloxapol 诱导的血脂异常中,Vo.Cr 可降低总胆固醇和甘油三酯水平。在高脂饮食诱导的血脂异常模型中,该植物提取物可显著降低总胆固醇、LDL-C、致动脉粥样硬化指数,并防止平均体重增加,同时增加 HDL-C。
这些数据表明,植物提取物的血管扩张作用是通过多种途径介导的,如抑制膜钙通道的 Ca(++)内流、细胞内储存的 Ca(++)释放和 NO 介导的途径,这可能解释了血压的下降。该植物还表现出体重减轻和抗血脂异常作用,这可能是由于抑制脂质的合成和吸收以及抗氧化活性。因此,本研究为堇菜属植物在高血压和血脂异常中的药用提供了药理学依据。